Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, ladies and gentlemen. Good afternoon. I'd like to welcome everyone to the TheraVans BioPharm first quarter 2025 conference call. During the presentation, all participants will be in a listen-only mode. A question in this session will follow company's formal remarks. To ask a question, press the star key followed by the digit 1 on your phone. Again, that is star 1 to ask a question. If listening via webcast, please mute audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference is being recorded. And now, I would like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir. Good afternoon, and welcome to TheraVance Biopharma's first quarter 2025 earnings results conference call. On slide two, you will find our forward-looking statements disclaimer, which covers certain risk factors which could cause actual results to differ materially from any forward-looking statements we might make in today's call, and which are described further in our filings with the SEC. Moving to slide three, I'm joined today by Rhonda Fardham, Chief Business Officer, Anya Miller, Head of Development, and Aziz Sawaf, Chief Financial Officer. Moving to slide four and beginning on the left-hand side, UPelry delivered solid results in the first quarter with net sales increasing 6% to just over $58 million. This performance was driven by a similar increase in demand as well as favorable pricing and channel mix. Building on the strong momentum we experienced in 2024, hospital doses increased 48% year on year. We are steadily advancing the Cypress trial consistent with our objective of enrolling the right patients at high performing sites and a...